The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of osimertinib resistance mechanisms using plasma cell-free DNA and tissue biopsy in EGFR-mutated T790M-positive Japanese patients with lung cancer.
 
Ryo Ariyasu
Employment - Takeda (I)
 
Ken Uchibori
No Relationships to Disclose
 
Kazuma Kiyotani
No Relationships to Disclose
 
Takahiro Yoshizawa
No Relationships to Disclose
 
Yosuke Dotsu
No Relationships to Disclose
 
Junji Koyama
No Relationships to Disclose
 
Masafumi Saiki
No Relationships to Disclose
 
Tomoaki Sonoda
No Relationships to Disclose
 
Shingo Nishikawa
No Relationships to Disclose
 
Satoru Kitazono
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
 
Noriko Yanagitani
Honoraria - Bristol-Myers Squibb; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
 
Atsushi Horiike
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Quintiles (Inst)
 
Makoto Nishio
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Ryohei Katayama
Speakers' Bureau - Chugai Pharma; Novartis; Pfizer
Research Funding - Daiichi Sankyo; Taiho Pharmaceutical; Toppan Printing Co.